Methicillin Resistant Staphylococcus Aureus (mrsa) Infections Therapeutics
1. Zyvox patent expiration
Treatment: Treatment of microbial infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(4 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6514529 | PFIZER | Oxazolidinone tablet formulation |
Mar, 2021
(4 years ago) | |
| US6559305 | PFIZER | Linezolid—crystal form II |
Jan, 2021
(4 years ago) | |
|
US6559305 (Pediatric) | PFIZER | Linezolid—crystal form II |
Jul, 2021
(4 years ago) | |
| US5688792 | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
Nov, 2014
(11 years ago) | |
|
US5688792 (Pediatric) | PFIZER | Substituted oxazine and thiazine oxazolidinone antimicrobials |
May, 2015
(10 years ago) | |
|
US6514529 (Pediatric) | PFIZER | Oxazolidinone tablet formulation |
Sep, 2021
(4 years ago) | |
Drugs and Companies using LINEZOLID ingredient
Market Authorisation Date: 18 April, 2000
Dosage: SOLUTION; TABLET; FOR SUSPENSION
How can I launch a generic of ZYVOX before it's drug patent expiration?
More Information on Dosage
ZYVOX family patents
